| Ranolazine, a new antianginal drug. | |
| | |
MedLine Citation:
|
PMID: 19804144 Owner: NLM Status: PubMed-not-MEDLINE |
Abstract/OtherAbstract:
|
The increasing and unmet social and economic burden of ischemic heart disease calls for new antianginal therapies. Ranolazine, a new antianginal agent, has a different mode of action from existing therapies, which act by decreasing indices of cardiac work. Ranolazine mainly affects the late sodium current across the membrane of cardiomyocytes, inducing a cascade of electrophysiologic and metabolic effects with the potential to reduce the cardiac ischemic burden without significantly changing blood pressure and heart rate. In clinical trials, ranolazine has been demonstrated to exert antianginal and anti-ischemic effects in chronic angina. It improves exercise performance, and decreases angina frequency and nitroglycerin use. Ranolazine is well tolerated at therapeutic doses. Larger studies are needed to explore the effects on hard end-points of morbidity and mortality. |
| | |
Authors:
|
Luigi Tavazzi |
Related Documents
:
|
2190464 - Evaluation of the efficacy and duration of action of isosorbide mononitrate in angina p... 11756214 - Laser revascularisation. 10455094 - Effect of an alpha(2) agonist (mivazerol) on limiting myocardial ischaemia in stable an... 2784824 - Effects of calcium channel blockers on the endothelial release of von willebrand factor... 22137254 - Prognostic value of exercise echocardiography in patients with hypertrophic cardiomyopa... 7399984 - Influence of exercise type, hydration, and heat on plasma volume shifts in men. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Future cardiology Volume: 1 ISSN: 1744-8298 ISO Abbreviation: Future Cardiol Publication Date: 2005 Jul |
Date Detail:
|
Created Date: 2009-10-06 Completed Date: 2009-12-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101239345 Medline TA: Future Cardiol Country: England |
Other Details:
|
Languages: eng Pagination: 447-55 Citation Subset: - |
Affiliation:
|
Institute of Care and Research, Divisione di Cardiologia, IRCCS Policlinico San Matteo, P.le Golgi, 227100 Pavia, Italy. l.tavazzi@smatteo.pv.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Losartan in cardiovascular disease.
Next Document: Postconditioning inhibits mitochondrial permeability transition.